NCT06651229View on ClinicalTrials.gov

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

August 5, 2027

Study Completion Date

December 1, 2028

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Interventions
DRUG

JNJ-90189892

JNJ-90189892 will be administered.

Trial Locations (8)

2139

RECRUITING

Concord Hospital, Concord

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

6009

RECRUITING

Sir Charles Gairdner Hospital, Nedlands

28040

RECRUITING

Hosp Univ Fund Jimenez Diaz, Madrid

31008

RECRUITING

Clinica Univ. de Navarra, Pamplona

31059

RECRUITING

Institut Claudius Regaud, Toulouse

41013

RECRUITING

Hospital Universitario Virgen Rocio, Seville

67200

RECRUITING

Institut de Cancerologie Strasbourg Europe ICANS, Strasbourg

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY